These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 32372673

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Medical progress: Acromegaly.
    Melmed S.
    N Engl J Med; 2006 Dec 14; 355(24):2558-73. PubMed ID: 17167139
    [No Abstract] [Full Text] [Related]

  • 45. Serum phosphate: Does it more closely reflect the true state of acromegaly?
    Xie T, Tian P, Wu S, Zhang X, Liu T, Gu Y, Sun C, Hu F.
    J Clin Neurosci; 2020 Jan 14; 71():26-31. PubMed ID: 31859176
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Large-scale second-hit AIP deletion causing a pediatric growth hormone-secreting pituitary adenoma: Case report and review of literature.
    Gummadavelli A, Dinauer C, McGuone D, Vining EM, Erson-Omay EZ, Omay SB.
    J Clin Neurosci; 2020 Aug 14; 78():420-422. PubMed ID: 32336638
    [Abstract] [Full Text] [Related]

  • 48. The causes and consequences of pituitary gigantism.
    Beckers A, Petrossians P, Hanson J, Daly AF.
    Nat Rev Endocrinol; 2018 Dec 14; 14(12):705-720. PubMed ID: 30361628
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51. Growth Hormone Excess: Implications and Management.
    Dhaneshwar S, Shandily S, Tiwari V.
    Endocr Metab Immune Disord Drug Targets; 2023 Dec 14; 23(6):748-763. PubMed ID: 36237164
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. [Outcome of somatostatin analogue treatment in acromegaly].
    Mondok A, Tóth M, Patócs A, Szücs N, Igaz P, Pusztai P, Czirják S, Beko G, Gláz E, Rácz K, Tulassay Z.
    Orv Hetil; 2009 Aug 02; 150(31):1457-62. PubMed ID: 19617182
    [Abstract] [Full Text] [Related]

  • 54. Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment.
    Brabant G.
    Eur J Endocrinol; 2003 Apr 02; 148 Suppl 2():S15-20. PubMed ID: 12670296
    [Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.
    Puglisi S, Ferraù F, Ragonese M, Spagnolo F, Cannavò S.
    Front Endocrinol (Lausanne); 2020 Apr 02; 11():28. PubMed ID: 32117056
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Decrease in growth hormone and insulin-like growth factor (IGF)-1 release and amelioration of acromegaly features after rosiglitazone treatment of type 2 diabetes mellitus a patient with acromegaly.
    Gradiser M, Matovinovic M, Vrkljan M.
    Croat Med J; 2007 Feb 02; 48(1):87-91. PubMed ID: 17309144
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.